Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | F2R | P25116 | 5/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4029675 | 0.86 | ADRA1A (0.41) | NPC1MAPTRAB9ASMN1; SMN2ADRA1A | |
| SCHEMBL3665945 | 0.85 | PROKR1 (0.44) | NPC1MAPTSTAT1RAB9ASMN1; SMN2 | |
| SCHEMBL3664098 | 0.84 | ADRA1A (0.54) | NPC1MAPTRAB9ASMN1; SMN2ADRA1A | |
| SCHEMBL3664232 | 0.84 | HDAC2 (0.44) | NPC1MAPTRAB9ASMN1; SMN2ADRA1A | |
| Hydrochloric Acid SCHEMBL4090130 | 0.83 | ADRA1A (0.52) | NPC1MAPTRAB9ASMN1; SMN2ADRA1A | |
| SCHEMBL3665381 | 0.83 | ADRA1A (0.44) | NPC1MAPTRAB9ASMN1; SMN2ADRA1A | |
| SCHEMBL3665034 | 0.82 | HIF1A (0.44) | NPC1MAPTSTAT1RAB9ASMN1; SMN2 | |
| SCHEMBL3663013 | 0.80 | MRGPRX4 (0.47) | NPC1RAB9AADRA1AS1PR5 | |
| SCHEMBL3665949 | 0.80 | ADRA1A (0.43) | NPC1RAB9ASMN1; SMN2ADRA1AALDH1A1 | |
| SCHEMBL21033483 | 0.79 | GABRA2 (0.46) | NPC1MAPTRAB9ASMN1; SMN2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288424-B2 | Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2235013-B1 | SUBSTITUTED TETRAHYDROIMIDAZOPYRIDINE COMPOUNDS AND THE USE THEREOF IN PHARMACEUTICALS | GRUENENTHAL GMBH (DE) | 2012-08-01 | — | — | EP | disclosed |
| EP-2083009-A1 | Substituted tetrahydroimidazopyridine compounds and their use in medicine | Grünenthal GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | HRH4, TRPV1, QDPR | NPC1 3247/4885MAPT 374/4885STAT1 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.